Yifeng Pharmacy Strategic Asset Allocation Index
Yifeng Pharmacy strategic asset allocation index. Yifeng Pharmacy (603939) has a Strategic Asset Allocation Index of 52.4% as of June 2023. Strategic assets (PP&E of CN¥5.13 Billion plus long-term investments of CN¥-) total CN¥5.13 Billion, measured against net assets of CN¥9.80 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Yifeng Pharmacy balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Yifeng Pharmacy (2011–2022)
Strategic asset allocation index of Yifeng Pharmacy from 2011 to 2022. This chart shows how Yifeng Pharmacy's Strategic Asset Allocation Index has evolved across 12 annual periods from 2011 to 2022. As of June 2023, the index stands at 52.4%, representing strategic assets of CN¥5.13 Billion against net assets of CN¥9.80 Billion CNY. Check how tangible is Yifeng Pharmacy's equity to evaluate the tangible quality of the company's equity base.
Yifeng Pharmacy Strategic Asset Allocation Index by Year (2011–2022)
Yifeng Pharmacy strategic asset allocation index by year from 2011 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Yifeng Pharmacy from 2011 to 2022, covering 12 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 603939 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 53.6% | CN¥4.89 Billion | CN¥4.89 Billion | CN¥- | CN¥9.12 Billion | ▼ -3.6 pp |
| 2021 | 57.3% | CN¥4.50 Billion | CN¥4.50 Billion | CN¥- | CN¥7.86 Billion | ▼ -4.1 pp |
| 2020 | 61.4% | CN¥3.55 Billion | CN¥3.55 Billion | CN¥- | CN¥5.78 Billion | ▲ +50.2 pp |
| 2019 | 11.2% | CN¥527.95 Million | CN¥527.95 Million | CN¥- | CN¥4.71 Billion | ▲ +0.5 pp |
| 2018 | 10.7% | CN¥446.13 Million | CN¥416.58 Million | CN¥29.55 Million | CN¥4.17 Billion | ▼ -1.2 pp |
| 2017 | 11.9% | CN¥376.86 Million | CN¥315.21 Million | CN¥61.65 Million | CN¥3.18 Billion | ▲ +1.7 pp |
| 2016 | 10.2% | CN¥303.20 Million | CN¥302.75 Million | CN¥450.00K | CN¥2.98 Billion | ▼ -8.5 pp |
| 2015 | 18.7% | CN¥265.90 Million | CN¥265.45 Million | CN¥450.00K | CN¥1.42 Billion | ▼ -9.1 pp |
| 2014 | 27.8% | CN¥165.62 Million | CN¥165.62 Million | CN¥- | CN¥595.76 Million | ▼ -2.1 pp |
| 2013 | 29.9% | CN¥150.32 Million | CN¥150.32 Million | CN¥- | CN¥502.20 Million | ▼ -4.6 pp |
| 2012 | 34.5% | CN¥146.97 Million | CN¥146.97 Million | CN¥- | CN¥425.82 Million | ▲ +10.7 pp |
| 2011 | 23.8% | CN¥84.70 Million | CN¥84.70 Million | CN¥- | CN¥356.28 Million | — |